A Phase 3, Interventional, Randomized, Multicenter, Open-Label Study of DCC-2618 vs Sunitinib in Patients with Advanced Gastrointestinal Stromal Tumors after Treatment with Imatinib (INTRIGUE)

Principal Investigator

Michael Heinrich

Study Purpose

The purpose of this study is to learn more about the safety of DCC 2618 (the study drug) and how well it works against cancer in patients who have received prior anticancer treatment. We will also look at how the study drug may affect your body.

Medical Condition(s)

Gastrointestinal Stromal Tumors who have Received Prior Treatment with Imatinib

Eligibility Criteria

>18 years of age with previously treated GIST. Various tests and exams will also be done to confirm eligibility.

Age Range

18 - 100

Healthy Volunteers Needed


Duration of Participation

You may receive the study drug for up to 2 years. You will have a safety follow up visit 30 days after your last dose of study drug and will continue to be contacted by the study staff every 3 months by phone or routine visits to collect long-term data related to your health.

Minors Included



Knight Clinical Trials Office


Deciphera Pharmaceuticals, LLC

Recruitment End


Compensation Provided


Go Back